The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Metagenomi Inc (NASDAQ: MGX) closed at $2.38 down -8.81% from its previous closing price of $2.61. In other words, the price has decreased by -$8.81 from its previous closing price. On the day, 0.67 million shares were traded.
Ratios:
For a deeper understanding of Metagenomi Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.18 and its Current Ratio is at 6.18. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 07, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $16 to $6.
On March 05, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $25.Wells Fargo initiated its Overweight rating on March 05, 2024, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 05 ’24 when Wapnick Pamela sold 1,559 shares for $1.86 per share. The transaction valued at 2,900 led to the insider holds 61,492 shares of the business.
Wapnick Pamela sold 6,265 shares of MGX for $18,043 on Sep 05 ’24. The Chief Financial Officer now owns 63,051 shares after completing the transaction at $2.88 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.62 while its Price-to-Book (P/B) ratio in mrq is 0.35.
Stock Price History:
Over the past 52 weeks, MGX has reached a high of $12.74, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is -21.92%, while the 200-Day Moving Average is calculated to be -32.71%.
Shares Statistics:
A total of 37.43M shares are outstanding, with a floating share count of 21.36M. Insiders hold about 42.91% of the company’s shares, while institutions hold 25.71% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.67 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$2.17 and -$2.84 for the fiscal current year, implying an average EPS of -$2.48. EPS for the following year is -$2.88, with 4.0 analysts recommending between -$2.6 and -$3.26.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $9.46M this quarter.It ranges from a high estimate of $20M to a low estimate of $1.5M. As of the current estimate, Metagenomi Inc’s year-ago sales were $12.4MFor the next quarter, 5 analysts are estimating revenue of $6.25M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 6 analysts have provided revenue estimates for MGX’s current fiscal year. The highest revenue estimate was $62.23M, while the lowest revenue estimate was $44.2M, resulting in an average revenue estimate of $51.7M. In the same quarter a year ago, actual revenue was $44.76MBased on 6 analysts’ estimates, the company’s revenue will be $33.16M in the next fiscal year. The high estimate is $61M and the low estimate is $10M.
